Mesoblast Priced, Nasdaq: MESO

Developing regenerative medicine based on adult stem cells.

Industry: Health Care

Latest Trade: $8.63 0.00 (0.0%)

First Day Return: +1.4%

Return from IPO: +7.9%

Industry: Health Care

We are a global leader in the field of regenerative medicine. We have leveraged our proprietary technology platform, which is based on specialized cells known as MLCs to establish what we believe to be the most advanced regenerative medicine product portfolio in the industry. We have what we believe to be an extensive safety profile for our product candidates, with over 1,340 patients treated. Based on outcomes in Phase 2 trials across multiple indications, we now have five MLC product candidates that are in active Phase 3 trials or are Phase 3-ready.
more less
IPO News for Mesoblast
more
IPO Data
IPO File Date 11/02/2015
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 7.5
Deal Size ($mm) $60
IPO Data
IPO Date 11/12/2015
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 7.5
Deal Size ($mm) $60
Underwriters
more
Company Data
Headquarters Melbourne, Australia
Founded 2004
Employees 115
Website www.mesoblast.com